Back to News
Market Impact: 0.25
Cellectar Reports 8-Year Complete Response With Iopofosine I 131; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Cellectar Biosciences reported a case study in which one administration of Iopofosine I 131 produced a complete response lasting more than eight years in a patient with aggressive diffuse large B-cell lymphoma. The report concerns a single patient and does not establish broader treatment outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
CLRB0.75
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- VCs will make billions on Anthropic’s IPO, but Amazon is set to make much (much) more